Technical Analysis for PKBO - Peak Bio Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | -5.71% | |
| Hot IPO Pullback | Bullish Swing Setup | -5.71% | |
| Narrow Range Bar | Range Contraction | -5.71% | |
| Inside Day | Range Contraction | -5.71% | |
| Gapped Up | Strength | -5.71% | |
| Hammer Candlestick | Bullish | -4.35% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Gapped Up (Partial) | 20 days ago |
| Up 3% | 20 days ago |
| Up 2% | 20 days ago |
| Up 1% | 20 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. Its lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is headquartered in Palo Alto, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Pharmaceutical Industry Life Sciences Biopharmaceutical Pharmacy Solid Tumors Alpha Inflammatory Acute Respiratory Distress Syndrome Antitrypsin Deficiency
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Pharmaceutical Industry Life Sciences Biopharmaceutical Pharmacy Solid Tumors Alpha Inflammatory Acute Respiratory Distress Syndrome Antitrypsin Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 1.75 |
| 52 Week Low | 1.05 |
| Average Volume | 6,227 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0000 |
| 20-Day Moving Average | 0.0000 |
| 10-Day Moving Average | 1.4863 |
| Average True Range | 0.1502 |
| RSI | 42.20 |
| ADX | 0.0 |
| +DI | 15.1750 |
| -DI | 47.5414 |
| Chandelier Exit (Long, 3 ATRs) | 1.2994 |
| Chandelier Exit (Short, 3 ATRs) | 1.5006 |
| Upper Bollinger Bands | 0.0000 |
| Lower Bollinger Band | 0.0000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0000 |
| MACD Line | -0.0581 |
| MACD Signal Line | -0.0269 |
| MACD Histogram | -0.0312 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.3200 | ||||
| Resistance 3 (R3) | 1.3200 | 1.3200 | 1.3200 | ||
| Resistance 2 (R2) | 1.3200 | 1.3200 | 1.3200 | 1.3200 | |
| Resistance 1 (R1) | 1.3200 | 1.3200 | 1.3200 | 1.3200 | 1.3200 |
| Pivot Point | 1.3200 | 1.3200 | 1.3200 | 1.3200 | 1.3200 |
| Support 1 (S1) | 1.3200 | 1.3200 | 1.3200 | 1.3200 | 1.3200 |
| Support 2 (S2) | 1.3200 | 1.3200 | 1.3200 | 1.3200 | |
| Support 3 (S3) | 1.3200 | 1.3200 | 1.3200 | ||
| Support 4 (S4) | 1.3200 |
